{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:25:57Z","timestamp":1793039157872,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results. The meta-analysis was performed to investigate the effects of baricitinib in COVID-19, by pooling data from all clinically randomized controlled trials (RCTs) available to increase power to testify.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Studies were searched in PubMed, Embase, and Cochrane Library databases on January 31, 2023. We performed a meta-analysis to estimate the efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19. This study is registered with INPLASY, number 202310086.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 3010 patients were included in our analyses. All included studies were randomized controlled trials or prospective\u00a0study. There was no difference in 14-day mortality between the two groups [OR 0.23 (95% CI 0.03\u20131.84), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200972%, <jats:italic>P<\/jats:italic>\u2009=\u20090.17]. In subgroup analyses we found that baricitinib did not seem to improve significantly in 24-day mortality critically ill patients [OR 0.60 (95% CI 0.35\u20131.02), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%, <jats:italic>P<\/jats:italic>\u2009=\u20090.06]. Fortunately, baricitinib have led to faster recovery and shorter hospital stays for COVID-19 patients. There were no difference in infections and infestations, major adverse cardiovascular events, deep vein thrombosis and pulmonary embolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baricitinib did not increase the incidence of adverse reactions. At the same time, we can find that it reduces the mortality of COVID-19 patients, not including the critically ill.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01403-0","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:02:01Z","timestamp":1700568121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"28","author":[{"given":"Jing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506.","journal-title":"China Lancet"},{"key":"1403_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"1403_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"1403_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"ACTT-2 Study Group Members","year":"2021","unstructured":"ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1403_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Phelan A, Grifn I. COVID-19: combining antiviral and anti-infammatory treatments. Lancet Infect Dis. 2020;20:400\u20132.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1403_CR6","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte V, Ugel S, Tinazzi E, Vella A, Sanctis DF, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409\u201316.","journal-title":"J Clin Invest"},{"key":"1403_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jinf.2021.02.023","volume":"82","author":"L Petrone","year":"2021","unstructured":"Petrone L, Petruccioli E, Alonzi T. In-vitro evaluation of the immunomodulatory effects of Baricitinib: implication for COVID-19 therapy. J Infect. 2021;82:58\u201366.","journal-title":"J Infect"},{"key":"1403_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaci.2020.08.031","volume":"147","author":"JT Sims","year":"2021","unstructured":"Sims JT, Krishnan V, Chang CY. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol. 2021;147:107\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1403_CR9","unstructured":"World Health Organization. Therapeutics and COVID-19 guideline development. 2022. https:\/\/www.who.int\/teams\/health-care-readiness\/covid-19\/therapeutics."},{"key":"1403_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"COV-BARRIER Study Group","year":"2021","unstructured":"COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebocontrolled phase 3 trial. Lancet Respir Med. 2021;9:1407\u201318.","journal-title":"Lancet Respir Med"},{"key":"1403_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"COV-BARRIER Study Group","year":"2022","unstructured":"COV-BARRIER Study Group. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327\u201336.","journal-title":"Lancet Respir Med"},{"key":"1403_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13054-022-04205-8","volume":"27","author":"EU SolidAct study group","year":"2023","unstructured":"EU SolidAct study group. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Crit Care. 2023;27:9.","journal-title":"Crit Care"},{"key":"1403_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339: b2700.","journal-title":"BMJ (Clinical research ed)"},{"key":"1403_CR14","unstructured":"Cochlane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. 2011 [J\/OL] [http: \/\/handbook-5\u20131. cochrane.org\/]."},{"issue":"7414","key":"1403_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, Deeks J. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical research ed)"},{"key":"1403_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1403_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui DS, Azhar IE, Madani TA, Ntoumi F, Kock R, Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2013 the latest 2019 novel coronavirus outbreak in Wuhan China. Int J Infect Dis. 2020;91:264\u20136.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"1403_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s11739-020-02356-6","volume":"15","author":"G Voiriot","year":"2020","unstructured":"Voiriot G, Fajac A, Lopinto J, Labb\u00e9 V, Fartoukh M. Bronchoalveolar lavage findings in severe COVID-19 pneumonia. Intern Emerg Med. 2020;15(7):1333\u20134.","journal-title":"Intern Emerg Med"},{"issue":"6","key":"1403_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355\u201362.","journal-title":"Nat Rev Immunol"},{"key":"1403_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22:57\u201365.","journal-title":"Nat Rev Immunol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01403-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01403-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01403-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:29:51Z","timestamp":1700605791000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01403-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01403-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"23 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors state no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"536"}}